Front Row Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.94K | Sell |
9
-5
| -36% | -$1.63K | ﹤0.01% | 456 |
|
|
2025
Q1 | $3.78K | Hold |
14
| – | – | ﹤0.01% | 426 |
|
|
2024
Q4 | $3.29K | Hold |
14
| – | – | ﹤0.01% | 426 |
|
|
2024
Q3 | $3.85K | Hold |
14
| – | – | ﹤0.01% | 421 |
|
|
2024
Q2 | $3.4K | Hold |
14
| – | – | ﹤0.01% | 794 |
|
|
2024
Q1 | $2.09K | Hold |
14
| – | – | ﹤0.01% | 843 |
|
|
2023
Q4 | $2.68K | Hold |
14
| – | – | ﹤0.01% | 403 |
|
|
2023
Q3 | $2.48K | Hold |
14
| – | – | ﹤0.01% | 788 |
|
|
2023
Q2 | $3K | Hold |
14
| – | – | ﹤0.01% | 743 |
|
|
2023
Q1 | $3K | Buy |
+14
| New | +$3K | ﹤0.01% | 751 |
|
|
2022
Q4 | – | Sell |
-14
| Closed | -$3K | – | 881 |
|
|
2022
Q3 | $3K | Hold |
14
| – | – | ﹤0.01% | 735 |
|
|
2022
Q2 | $2K | Hold |
14
| – | – | ﹤0.01% | 796 |
|
|
2022
Q1 | $2K | Hold |
14
| – | – | ﹤0.01% | 838 |
|
|
2021
Q4 | $2K | Hold |
14
| – | – | ﹤0.01% | 863 |
|
|
2021
Q3 | $3K | Hold |
14
| – | – | ﹤0.01% | 804 |
|
|
2021
Q2 | $3K | Hold |
14
| – | – | ﹤0.01% | 806 |
|
|
2021
Q1 | $2K | Hold |
14
| – | – | ﹤0.01% | 850 |
|
|
2020
Q4 | $2K | Hold |
14
| – | – | ﹤0.01% | 812 |
|
|
2020
Q3 | $2K | Hold |
14
| – | – | ﹤0.01% | 810 |
|
|
2020
Q2 | $2K | Hold |
14
| – | – | ﹤0.01% | 814 |
|
|
2020
Q1 | $2K | Hold |
14
| – | – | ﹤0.01% | 790 |
|
|
2019
Q4 | $2K | Hold |
14
| – | – | ﹤0.01% | 766 |
|
|
2019
Q3 | $1K | Hold |
14
| – | – | ﹤0.01% | 842 |
|
|
2019
Q2 | $1K | Hold |
14
| – | – | ﹤0.01% | 921 |
|
|
2019
Q1 | $1K | Buy |
+14
| New | +$1K | ﹤0.01% | 921 |
|